Request Demo
CSL Seqirus scores 4th award from US government for bird flu pandemic preparedness
VaccinePhase 2
The U.S. government has expanded its bird flu pandemic preparedness partnership with CSL Seqirus. It is the fourth award from the Biomedical Advanced Research and Development Authority (BARDA) to the company.
The United States Department of Health and Human Services has expanded its avian flu CSL SeqirusCSL Seqiruseparedness partnership with CSL SeBiomedical Advanced Research and Development Authority (BARDA)inish process for the shots.
Execution of this stage will increase the arsenal of vaccines acquired by the Biomedical Advanced Research and Development ACSL SeqirusARDA) under its National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program.
It is the fourth award from BARDA to CSL Seqirus related to preparations for aBiomedical Advanced Research and Development Authority (BARDA) been detected in wild birds and Influenza throughout the U.S.
With this agreement, CSL SeqBARDAwillCSL Seqirus8 million vaccine doses that are matched to the curreavian influenzaof the virus.
On Thursday, the CDC CSL Seqirus the spread of H5N1 in dairy cattle and two cases of humans contracting the virus.
“The CDC maintains the risk to public health as low. We are closely monitoring the situation because we are acutely aware of the threat that influenza virus strains like H5N1 can pose and take seriously our role in preparedness efforts alongside our government and public health partners,” Marc Lacey, CSL Seqirus, Global Executive Director for Pandemic, said in a release.
CSL will provide the vaccines from its massive manufacturing site in Holly Springs, N.C. which was built through a public-private partnershipinfluenzathe company and BARDA 15 years ago.
Two years ago, CSL Seqirus gained a “ready to respond” designation, meaning that in the case of a pandemic, it would immediately shift from its usual production of seasonal flu shots to the manufacture of those for the emergency.
Of the potential $2 billion award amount from the government to CSL Seqirus, BARDA has obligated $1.1 billion to the company, with $139 million of that paid for, acseasonal fluSASpending.com.
In October 2022, CSL Seqirus scored a $30 million contract from CSL SeqirusndBARDA phase 2 trial of its avian flu candidate. In August of last year, BARDA awarded a $46.3 million contract to the company for one bulk lot of HPAI vaccines.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.